Ipamorelin (10mg)

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Unlike earlier GHS compounds such as GHRP-6 and GHRP-2, ipamorelin is notable for its high selectivity — it stimulates growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels at GH-stimulating doses. This selectivity was first characterized by Raun and colleagues at Novo Nordisk in 1998. Ipamorelin binds GHS-R1a on pituitary somatotroph cells, triggering intracellular calcium influx via phospholipase C and IP3 pathways. This calcium mobilization causes GH-containing granule fusion with the cell membrane and GH exocytosis. The peptide produces dose-dependent GH release with a well-defined dose-response curve and a ceiling effect, meaning higher doses do not produce proportionally greater GH release — a property that contributes to its safety profile. Research has also explored ipamorelin's effects on gastrointestinal motility. Hansen et al. demonstrated that ipamorelin accelerates gastric emptying and colonic transit time in post-operative ileus models, leading to investigation as a potential prokinetic agent. This GI activity is mediated through ghrelin receptor activation in the enteric nervous system.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Unlike earlier GHS compounds such as GHRP-6 and GHRP-2, ipamorelin is notable for its high selectivity — it stimulates growth hormone release without significantly affecting cortisol, prolactin, or ACTH levels at GH-stimulating doses. This selectivity was first characterized by Raun and colleagues at Novo Nordisk in 1998. Ipamorelin binds GHS-R1a on pituitary somatotroph cells, triggering intracellular calcium influx via phospholipase C and IP3 pathways. This calcium mobilization causes GH-containing granule fusion with the cell membrane and GH exocytosis. The peptide produces dose-dependent GH release with a well-defined dose-response curve and a ceiling effect, meaning higher doses do not produce proportionally greater GH release — a property that contributes to its safety profile. Research has also explored ipamorelin's effects on gastrointestinal motility. Hansen et al. demonstrated that ipamorelin accelerates gastric emptying and colonic transit time in post-operative ileus models, leading to investigation as a potential prokinetic agent. This GI activity is mediated through ghrelin receptor activation in the enteric nervous system.

In animal studies, ipamorelin is typically dosed at 0.1-1 mg/kg. The selective GH release window is observed at doses up to 1 mg/kg, above which ACTH stimulation begins. Human phase II trials for post-operative ileus used IV infusions of 0.03 mg/kg/hr.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.